Abbreviations
BEVA+FOLFOX4
FOLFOX4
286
291
Phase:
3
Open label
CRC
Any
meta
L2
- histologically confirmed colorectal cancer that was advanced or metastatic and measurable as defined by the Responsedc-returnEvaluation Criteria in Solid Tumors (RECIS T)dc-return- prior chemotherapy with irinotecan and a fluoropyrimidine for advanced disease was requireddc-return- a history of hypertension was allowed provided that blood pressure readings were maintained below 150/100 mmHg on a stable antihypertensive regimendc-return- baseline urinalysis demonstrating protein were required to have less than 500 mg of protein excreted over a 24-hour period
- previous use of oxaliplatin or bevacizumab was not permitteddc-return- a history of major surgery within 28 daysdc-return- radiotherapy within 14 daysdc-return- hypersensitivity to recombinant murine monoclonal antibodiesdc-return- a thrombotic or hemorrhagic event within 6 months of study entrydc-return- those patients requiring therapeutic anticoagulationdc-return- low-dose warfarin used for the maintenance of venous access devices was permitted, as was daily aspirin use of 325 mg or less